162 related articles for article (PubMed ID: 26909279)
1. Bone-targeted agent use for bone metastases from breast cancer and prostate cancer: A patient survey.
Hutton B; Morretto P; Emmenegger U; Mazzarello S; Kuchuk I; Addison CL; Crawley F; Canil C; Malone S; Berry S; Fergusson D; Clemons M
J Bone Oncol; 2013 Sep; 2(3):105-9. PubMed ID: 26909279
[TBL] [Abstract][Full Text] [Related]
2. Perceptions around bone-modifying agent use in patients with bone metastases from breast and castration resistant prostate cancer: a patient survey.
Alzahrani M; Clemons M; Sienkiewicz M; Shrem NS; McGee SF; Vandermeer L; Sehdev S; Savard MF; Awan A; Canil C; Hutton B; Pond G; Saunders D; Ng T
Support Care Cancer; 2021 Nov; 29(11):6903-6912. PubMed ID: 34023950
[TBL] [Abstract][Full Text] [Related]
3. A real-world study assessing the use of bone-targeted agents and their impact on bone metastases in patients with prostate cancer treated in clinical practice in Europe.
Body JJ; von Moos R; Rider A; Hallworth P; Bhowmik D; Gatta F; Hechmati G; Qian Y
J Bone Oncol; 2019 Feb; 14():100212. PubMed ID: 30627511
[TBL] [Abstract][Full Text] [Related]
4. De-escalated administration of bone-targeted agents in patients with breast and prostate cancer-A survey of Canadian oncologists.
Hutton B; Addison C; Mazzarello S; Joy AA; Bouganim N; Fergusson D; Clemons M
J Bone Oncol; 2013 Jun; 2(2):77-83. PubMed ID: 26909274
[TBL] [Abstract][Full Text] [Related]
5. Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in real-world practice in six European countries.
von Moos R; Body JJ; Rider A; de Courcy J; Bhowmik D; Gatta F; Hechmati G; Qian Y
J Bone Oncol; 2018 Jun; 11():1-9. PubMed ID: 29892519
[TBL] [Abstract][Full Text] [Related]
6. Two-year results of a randomised trial comparing 4- versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancer.
Clemons M; Liu M; Stober C; Pond G; Jemaan Alzahrani M; Ong M; Ernst S; Booth C; Mates M; Abraham Joy A; Aseyev O; Blanchette P; Vandermeer L; Tu M; Thavorn K; Fergusson D;
J Bone Oncol; 2021 Oct; 30():100388. PubMed ID: 34567960
[TBL] [Abstract][Full Text] [Related]
7. Real-world practice patterns and attitudes towards de-escalation of bone-modifying agents in patients with bone metastases from breast and prostate cancer: A physician survey.
AlZahrani M; Clemons M; Vandermeer L; Sienkiewicz M; Awan AA; Hutton B; Pond GR; Ng TL
J Bone Oncol; 2021 Feb; 26():100339. PubMed ID: 33294318
[TBL] [Abstract][Full Text] [Related]
8. Treatment and pattern of bone metastases in 1094 patients with advanced breast cancer - Results from the prospective German Tumour Registry Breast Cancer cohort study.
Schröder J; Fietz T; Köhler A; Petersen V; Tesch H; Spring L; Fleitz A; Jänicke M; Marschner N;
Eur J Cancer; 2017 Jul; 79():139-148. PubMed ID: 28494404
[TBL] [Abstract][Full Text] [Related]
9. Bone-targeting agents in major solid tumour metastases: a multinational cohort study.
Kim JH; Shen CY; Au PC; Baek YH; Cheung CL; Chung WP; Kleinman NJ; Lam TC; Liao TC; Lin TC; Shin JY; Sing CW; Wong ICK; Lai EC
BMJ Support Palliat Care; 2024 Jan; 13(e3):e1064-e1073. PubMed ID: 35177433
[TBL] [Abstract][Full Text] [Related]
10. Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in the United States.
Henry D; von Moos R; Body JJ; Rider A; De Courcy J; Bhowmik D; Gatta F; Hechmati G; Qian Y
Curr Med Res Opin; 2019 Mar; 35(3):375-381. PubMed ID: 30550358
[TBL] [Abstract][Full Text] [Related]
11. Bisphosphonates and other bone agents for breast cancer.
Wong MH; Stockler MR; Pavlakis N
Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
[TBL] [Abstract][Full Text] [Related]
12. Patterns of care for patients with metastatic bone disease in solid tumors: A cross-sectional study from Switzerland (SAKK 95/16).
Mark M; Thürlimann B; Ribi K; Schär C; Dietrich D; Cathomas R; Zürrer-Härdi U; von Briel T; Anchisi S; Bohanes P; Blum V; von Burg P; Mannhart M; Caspar CB; von Moos R
J Bone Oncol; 2020 Apr; 21():100273. PubMed ID: 31970055
[TBL] [Abstract][Full Text] [Related]
13. Bisphosphonates for breast cancer.
Pavlakis N; Schmidt R; Stockler M
Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
[TBL] [Abstract][Full Text] [Related]
14. Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options.
Gartrell BA; Coleman R; Efstathiou E; Fizazi K; Logothetis CJ; Smith MR; Sonpavde G; Sartor O; Saad F
Eur Urol; 2015 Nov; 68(5):850-8. PubMed ID: 26153564
[TBL] [Abstract][Full Text] [Related]
15. Should de-escalation of bone-targeting agents be standard of care for patients with bone metastases from breast cancer? A systematic review and meta-analysis.
Ibrahim MF; Mazzarello S; Shorr R; Vandermeer L; Jacobs C; Hilton J; Hutton B; Clemons M
Ann Oncol; 2015 Nov; 26(11):2205-13. PubMed ID: 26122727
[TBL] [Abstract][Full Text] [Related]
16. Impact of Extraskeletal Metastases on Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer with Bone Metastases.
Lobo-Martins S; Ferreira AR; Mansinho A; Casimiro S; Leitzel K; Ali S; Lipton A; Costa L
Cancers (Basel); 2020 Jul; 12(8):. PubMed ID: 32722128
[TBL] [Abstract][Full Text] [Related]
17. Treatment dynamics of bone-targeting agents among men with bone metastases from prostate cancer in the United States.
Butler AM; Cetin K; Hernandez RK; Diane Reams B; Overman RA; I Kim J; Hirsch BR; Abernethy AP; Liede A; Alan Brookhart M
Pharmacoepidemiol Drug Saf; 2018 Feb; 27(2):229-238. PubMed ID: 29316026
[TBL] [Abstract][Full Text] [Related]
18. Bone-Targeted Agents in Breast Cancer: Do We Now Have All the Answers?
Ottewell P; Wilson C
Breast Cancer (Auckl); 2019; 13():1178223419843501. PubMed ID: 31555046
[TBL] [Abstract][Full Text] [Related]
19. A systematic review of dosing frequency with bone-targeted agents for patients with bone metastases from breast cancer.
Hutton B; Addison CL; Campbell K; Fergusson D; Mazarello S; Clemons M
J Bone Oncol; 2013 Sep; 2(3):123-31. PubMed ID: 26909282
[TBL] [Abstract][Full Text] [Related]
20. Randomized feasibility study of de-escalated (every 12 wk) versus standard (every 3 to 4 wk) intravenous pamidronate in women with low-risk bone metastases from breast cancer.
Amir E; Freedman O; Carlsson L; Dranitsaris G; Tomlinson G; Laupacis A; Tannock IF; Clemons M
Am J Clin Oncol; 2013 Oct; 36(5):436-42. PubMed ID: 22781385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
